Larry Corey, MD, co-founder of Juno Therapeutics, may soon launch another drug company, according to STAT.
Celgene acquired Juno Therapeutics for $9 billion in 2018.
U.S. Securities and Exchange Commission filings show Dr. Corey, as well as two apparent family members — Daniel Corey, MD, and Jordan Corey — raised $43 million in November for a San Francisco-based immunotherapy company called CERo Therapeutics. The company has raised a total of $45 million since it was incorporated in 2016.
Dr. Daniel Corey was listed as CERo's CEO in the SEC filings and chief scientific officer in a recent conference agenda. Jordan Corey was listed as CFO. Dr. Larry Corey's role is unclear. He was listed as "executive officer" in SEC filings and as the company's secretary in state filings.
Dr. Larry Corey is the principal investigator for the HIV Vaccine Trials Network and a former president and director of the Fred Hutchinson Cancer Research Center, according to STAT.
Patent filings show CERo will use "chimeric engulfment receptors" to develop drugs, which may be why the company chose its name. It may focus on developing drugs for cancer and cell therapies for neurodegenerative diseases, the patent filings indicate.
Read the full article here.
More articles on pharmacy:
Novartis pays $9.7B to acquire Medicines Co.
Drug importation plan will be released 'soon,' Trump tweets
From data analytics to biosimilars — How 5 pharmacy leaders are tackling drug pricing